XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.22.1

SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition | The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement during the three months ended March 31, 2022 (in thousands):
Opening balance, December 31, 2021 | $ | 32,333 |
Payments received in advance | — |
Payments receivable | 1,508 |
Revenue from performance obligations satisfied during reporting period | (2,352) |
Closing balance, March 31, 2022 | $ | 31,489 |
Current portion of deferred revenue | $ | 14,260 |
Long-term portion of deferred revenue | 17,229 |
Total deferred revenue, March 31, 2022 | $ | 31,489 |
The following table presents our contract revenues disaggregated by timing of revenue recognition and excludes royalty revenue (in thousands):
| Three Months Ended March 31, 2022 |  |
| Point in Time |  | Over Time |  |  |  |
Revenue from Mundipharma Collaboration Agreement: |  |  |  |  |  |  |
Research and Development Services | $ | — |  |  | $ | 2,274 |  |  |  |  |
Clinical Supply Services | — |  |  | 252 |  |  |  |  |
Total revenue from Mundipharma Collaboration Agreement | $ | — |  |  | $ | 2,526 |  |  |  |  |
Revenue from Janssen Collaboration Agreement: |  |  |  |  |  |  |
License of Intellectual Property | $ | 816 |  |  | $ | — |  |  |  |  |
Research and Development Services | — |  |  | 2,356 |  |  |  |  |
Clinical Supply Services | — |  |  | 1,411 |  |  |  |  |
Total revenue from Janssen Collaboration Agreement | $ | 816 |  |  | $ | 3,767 |  |  |  |  |
| Three Months Ended March 31, 2021 |  |
| Point in Time |  | Over Time |  |  |  |
Revenue from Mundipharma Collaboration Agreement: |  |  |  |  |  |  |
Research and Development Services | $ | — |  |  | $ | 2,331 |  |  |  |  |
Clinical Supply Services | — |  |  | 77 |  |  |  |  |
Total revenue from Mundipharma Collaboration Agreement | $ | — |  |  | $ | 2,408 |  |  |  |  |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration